Cost implications of new evidence on prevention of cardiovascular disease

Research output: Contribution to journalReview article

1 Scopus citations


Due to the high morbidity, mortality and medical costs associated with cardiovascular diseases, the efficiency of western healthcare economies as a whole depends largely on the cost effectiveness of cardiovascular disease preventive interventions. In this review, the cost implications of new evidence relating to the treatment of cardiovascular disease risk factors are examined. In patients with hypertension, low-dose diuretics have been proven to be both the most effective and least costly first-line therapy. Recent data support more aggressive use of antihypertensive and lipid-lowering therapies in patients with myocardial infarction and other high-risk individuals such as diabetics. The use of behavioral and pharmacologic smoking cessation interventions and emerging screening or diagnostic approaches such as C-reactive protein testing and coronary calcium scanning are also discussed.

Original languageEnglish (US)
Pages (from-to)183-192
Number of pages10
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number2
StatePublished - Apr 1 2005


  • Cardiovascular disease
  • Cost implications

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cost implications of new evidence on prevention of cardiovascular disease'. Together they form a unique fingerprint.

  • Cite this